Keyword: Yescarta (axicabtagene ciloleucel)
The cell and gene therapy fields remain in early stages, but Novartis' CEO sees a big future. He's working to position Novartis ahead of the pack.
With Gilead’s CEO on the way out and revenues tumbling, the company needs a leader who can pump up cancer sales. And it may have found just that.
Gilead and Novartis are working to ramp up launches of their CAR-T drugs, and both companies are hoping longer-term data will help do the trick.
Gilead's third-quarter results offered a glimmer of hope for continued growth—particularly in HIV—but Wall Street skeptics weren't convinced.
NICE may have rejected it, but thanks to a new discount, Yescarta's beating archrival Kymriah to adult lymphoma patients on England's health service.
NICE rejected Novartis' Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma after two prior therapies.
Juno didn't immediately report CAR-T trial deaths, investors argued in a lawsuit, and now the sides have inked a $24 million settlement.
England's cost-effectiveness watchdogs gave Novartis the go-ahead for its CAR-T drug, Kymriah, to treat leukemia.
In a busy week at the European Commission, Novartis’ Kymriah, Gilead’s Yescarta, Jazz's Vyxeos, Alnylam's Onpattro and others got approvals.
Gilead has some big commercial challenges looming, and it’s poached an Amgen executive to spearhead them.